SCHEMBL19638178

SCHEMBL19638178

N#Cc1sc(NC(=O)c2ccc(C(=O)O)s2)nc1-c1ccccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.54
ADORA2A P29274 2/20 0.48
KMT2A Q03164 6/20 0.42
MEN1 O00255 5/20 0.42
ESRRG P62508 3/20 0.41
NPC1 O15118 6/20 0.40
RAB9A P51151 6/20 0.40
RXFP1 Q9HBX9 3/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
ALDH1A1 P00352 3/20 0.40
NPSR1 Q6W5P4 3/20 0.38
KDM4E B2RXH2 2/20 0.38
TP53 P04637 2/20 0.38
ADORA1 P30542 1/20 0.37
LMNA P02545 3/20 0.37
CASP3 P42574 2/20 0.37
SENP8 Q96LD8 2/20 0.37
SENP7 Q9BQF6 2/20 0.37
SENP6 Q9GZR1 2/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19637993 0.85 ADORA2A (0.65) ADORA3ADORA2AKMT2AMEN1NPC1
SCHEMBL19638113 0.83 ADORA2A (0.54) ADORA3ADORA2AKMT2AMEN1ESRRG
SCHEMBL19638106 0.81 ADORA3 (0.56) ADORA3ADORA2AKMT2AMEN1ESRRG
SCHEMBL19638109 0.80 ADORA3 (0.53) ADORA3ADORA2AKMT2AMEN1NPC1
SCHEMBL19638250 0.79 ADORA2A (0.54) ADORA3ADORA2AKMT2AMEN1ESRRG
SCHEMBL19637999 0.78 ADORA2A (0.59) ADORA3ADORA2AKMT2AMEN1NPC1
SCHEMBL1846915 0.77 ADORA3 (0.65) ADORA3ADORA2ANPC1RAB9AADORA1
SCHEMBL1849924 0.77 ADORA3 (0.49) ADORA3ADORA2AKMT2ANPC1RAB9A
SCHEMBL1848428 0.77 ADORA3 (0.65) ADORA3ADORA2ANPC1RAB9AADORA1
SCHEMBL1850969 0.77 ADORA3 (0.65) ADORA3ADORA2ANPC1RAB9AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207445-B Adenosine A3Modulators of receptors 帕罗生物制药有限公司 2021-03-16 CN claimed
EP-3248964-B1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA SL (ES) 2019-07-17 EP claimed
US-10238637-B2 Modulators of the adenosine A3 receptors PALOBIOFARMA, S.L. (ES) 2019-03-26 US claimed
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS PALOBIOFARMA, S.L. (ES) 2018-09-20 US claimed
EP-3248964-A1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA S.L. (ES) 2017-11-29 EP claimed
CN-107207445-B Adenosine A3Modulators of receptors 帕罗生物制药有限公司 2021-03-16 CN disclosed
EP-3248964-B1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA SL (ES) 2019-07-17 EP disclosed
US-10238637-B2 Modulators of the adenosine A3 receptors PALOBIOFARMA, S.L. (ES) 2019-03-26 US disclosed
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS PALOBIOFARMA, S.L. (ES) 2018-09-20 US disclosed
EP-3248964-A1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA S.L. (ES) 2017-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS ADORA3, ADORA2A, ADORA1 ADORA3 1/4885ADORA2A 2/4885KMT2A 4093/4885
US-10238637-B2 Modulators of the adenosine A3 receptors ADORA3, ADORA2A, ADORA1 ADORA3 1/4885ADORA2A 2/4885KMT2A 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.